Name: Recce Pharmaceuticals (RCE) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

RCE

Pharmaceuticals, Biotechnology & Life Sciences

Recce Pharmaceuticals

Short interest: 0.00%; 0.00 pp 30d; as of 9 Oct 2026
Reported shorts: 4.5K
Shares on issue: 305.770M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd is an Australian pharmaceutical company focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs. Their lead candidate, RECCE® 327, has received Qualified Infectious Disease Product (QIDP) designation from the FDA, offering potential market exclusivity. The company aims to provide effective treatments against a broad range of bacteria and viral indications.

Company profile →

Recce Pharmaceuticals (ASX:RCE) has 0.00% of its shares on issue reported as short positions as of 9 Oct 2026, or about 4,522 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.37% in August 2021. RCE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads RCE today

Zanger BreakoutWatchScore 16rank 1474 of 1942
CAN SLIMWatchScore 7rank 1444 of 1541
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 10rank 1279 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

RCE fundamentals

In the year to 30 Jun 2026, Recce Pharmaceuticals (ASX:RCE) recorded revenue of A$9.9M and a net loss after tax of A$15.0M. A year earlier it recorded revenue of A$7.7M and a net loss after tax of A$21.4M. Year-on-year growth: revenue +29.0% (FY). Net margin −150.5% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →